Under the agreement, Celularity will provide Arthrex exclusive rights to distribute its placental-derived regenerative orthopedic products.
“Partnering with Celularity positions us to explore new opportunities in the orthobiologics space while continuing our mission of helping surgeons better treat their patients,” Arthrex senior director of orthobiologics, David Shepard, said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
